Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2025 08:30 ET | Source: Actinogen Medical

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces the successful conduct of its scheduled Type C meeting (written response) on Alzheimer’s disease (AD) with...
April 30, 2025 08:00 ET | Source: Actinogen Medical

Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news

SYDNEY, April 30, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by...
June 14, 2022 07:46 ET | Source: Actinogen Medical

Actinogen Announces Phase 2 Trials in Alzheimer's Disease and Depression

SYDNEY, June 14, 2022 (GLOBE NEWSWIRE) -- Actinogen Medical Limited recently announced positive results for Part A of its two-part double-blind placebo-controlled XanaMIA dose-ranging trial, which...